Amgen (AMGN) Accumulated Expenses (2009 - 2026)

Amgen has reported Accumulated Expenses for 18 years, with the latest figure at $17.2 billion in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 14.45% year-over-year to $17.2 billion in Q2 2026; TTM through Jun 2026 was $17.2 billion, a 14.45% increase from a year earlier, with the FY2025 full-year figure at $18.5 billion, up 5.0% from the prior year.
• Accumulated Expenses was $17.2 billion for Q2 2026 at Amgen, up from $16.6 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $18.5 billion in Q4 2025, with the low at $10.5 billion in Q2 2022.
• Average Accumulated Expenses over 5 years is $14.6 billion, with a median of $14.4 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses soared 30.09% in 2023, then declined 3.78% in 2026.
• Over 5 years, Accumulated Expenses stood at $12.5 billion in 2022, then increased by 22.64% to $15.4 billion in 2023, then advanced by 14.86% to $17.6 billion in 2024, then advanced by 5.0% to $18.5 billion in 2025, then retreated by 7.19% to $17.2 billion in 2026.
• The last three Accumulated Expenses figures came in at $17.2 billion (Q2 2026), $16.6 billion (Q1 2026), and $18.5 billion (Q4 2025), per Business Quant data.